Detalhe da pesquisa
1.
Drug transporters of platinum-based anticancer agents and their clinical significance.
Drug Resist Updat
; 14(1): 22-34, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21251871
2.
Interaction of Cisplatin with the human organic cation transporter 2.
Clin Cancer Res
; 14(12): 3875-80, 2008 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18559608
3.
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
Cancer Chemother Pharmacol
; 62(5): 841-7, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18204842
4.
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Cancer Chemother Pharmacol
; 60(4): 569-79, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17256132
5.
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Cancer Chemother Pharmacol
; 59(3): 407-12, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17051369
6.
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Cancer Biol Ther
; 5(9): 1105-10, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16969123
7.
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Cancer Biol Ther
; 5(7): 833-9, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16775418
8.
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clin Cancer Res
; 11(22): 8097-104, 2005 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16299241
9.
Effects of St. John's wort on irinotecan metabolism.
J Natl Cancer Inst
; 94(16): 1247-9, 2002 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-12189228
10.
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
J Clin Oncol
; 20(5): 1222-31, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11870164
11.
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer Biol Ther
; 4(5): 555-60, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15917657
12.
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer Biol Ther
; 4(6): 650-8, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15908806
13.
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clin Cancer Res
; 8(3): 856-62, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11895919
14.
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Curr Cancer Drug Targets
; 2(2): 103-23, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12188913
15.
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Clin Colorectal Cancer
; 14(1): 18-24.e1, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25591799
16.
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Clin Pharmacol Ther
; 74(4): 364-71, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14534523
17.
Mechanism-based models for topotecan-induced neutropenia.
Clin Pharmacol Ther
; 76(6): 567-78, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15592328
18.
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clin Pharmacol Ther
; 75(5): 448-54, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15116057
19.
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Clin Pharmacokinet
; 42(7): 665-85, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12844327
20.
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
J Chromatogr B Analyt Technol Biomed Life Sci
; 795(2): 383-8, 2003 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-14522044